These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36681832)

  • 1. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
    Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
    Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.
    Yang JH; Sun XS; Xiao BB; Liu LT; Guo SS; Liang JD; Jia GD; Tang LQ; Chen QY; Mai HQ
    BMC Cancer; 2021 May; 21(1):534. PubMed ID: 33975558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
    BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
    Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
    ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in locally recurrent nasopharyngeal carcinoma patients.
    Sun XS; Zhu MY; Wen DX; Luo DH; Sun R; Chen QY; Mai HQ
    Radiother Oncol; 2022 Mar; 168():61-68. PubMed ID: 35101468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
    Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
    Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
    Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
    Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
    Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
    Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance.
    Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
    Cancer Res Treat; 2019 Oct; 51(4):1259-1268. PubMed ID: 30653745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the suitability of definitive radiation therapy in patients with metastatic nasopharyngeal carcinoma based on PET/CT: a large cohort study.
    Yang ZC; Hu YY; Liu LT; Guo SS; Du CC; Liang YJ; Chen QY; Mai HQ
    Eur Radiol; 2022 Nov; 32(11):7722-7732. PubMed ID: 35505116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.
    Li WZ; Hua X; Xie DH; Liang H; Liu GY; Xia WX; Xiang YQ
    ESMO Open; 2021 Feb; 6(1):100004. PubMed ID: 33399071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
    Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M1 stage subdivisions based on
    Qiu HZ; Zhang X; Liu SL; Sun XS; Mo YW; Lin HX; Lu ZJ; Guo J; Tang LQ; Mai HQ; Liu LT; Guo L
    Ther Adv Med Oncol; 2022; 14():17588359221118785. PubMed ID: 35983026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
    Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
    Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
    Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
    BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Zong J; Ji P; Lin C; Zhang R; Chen Y; Lu Q; Peng X; Pan J; Lin S
    Oral Oncol; 2022 Aug; 131():105972. PubMed ID: 35728415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
    Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
    Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
    Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
    Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.